InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (6 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
6
T+90 hit rate
0%
T+90 mean return
-32.9%
Across 5 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Trager James, Directeur Scientifique. Officer active across 1 company, notably Nkarta, Inc.. Cumulatively, 14 reports have been published. Breakdown: 0 buy · 6 sells. Total volume traded: €158k. History available since 3 May 2021. The latest transaction was disclosed on 18 June 2024 (Cession). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations14 total
456 shares@ US$5.601.2% of flowCommon StockSEC:0000950170-24-075733:0
4,143 shares@ US$12.0024.0% of flowCommon StockSEC:0000950170-24-015564:0
4,560 shares@ US$8.7419.0% of flowCommon StockSEC:0000950170-24-005429:0
56,000 shares0Common StockSEC:0001209191-24-001161:0
439 shares@ US$4.851.0% of flowCommon StockSEC:0001209191-23-039061:0
37,500 shares0Common StockSEC:0001209191-23-003857:0
5,000 shares@ US$3.8910.0% of flowCommon StockSEC:0000899243-22-028991:0
5,000 shares0Common StockSEC:0001209191-22-038525:0
12,800 shares0Common StockSEC:0001209191-22-003754
12,800 shares0Common StockSEC:0001209191-22-003754:0
2,250 shares@ US$3.890.0039% mcap8.6% of flowCommon StockSEC:0000899243-21-031622:0
2,250 shares@ US$3.893.8% of flowCommon StockSEC:0000899243-21-031622
1,350 shares@ US$31.6441.4% of flowCommon StockSEC:0000899243-21-018300
1,350 shares@ US$31.640.019% mcap41.4% of flowCommon StockSEC:0000899243-21-018300:0
14 of 14 declarations
About Trager James
Trager James serves as Chief Scientific Officer at Nkarta, Inc. In this role, he oversees the company's research and development activities, focusing on innovation and scientific advancement. His expertise in the life sciences enables him to lead critical research projects and collaborate with multidisciplinary teams. Trager James is committed to advancing Nkarta's mission of improving treatments for patients.
